Related references
Note: Only part of the references are listed.Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
Yoshiya Tanaka et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry
Jeffrey D. Greenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Golimumab Pharmacokinetics After Repeated Subcutaneous and Intravenous Administrations in Patients with Rheumatoid Arthritis and the Effect of Concomitant Methotrexate: An Open-Label, Randomized Study
Yanli Zhuang et al.
CLINICAL THERAPEUTICS (2012)
Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy A Meta-analysis
Maria A. Lopez-Olivo et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
Yvonne M. R. de Punder et al.
RHEUMATOLOGY (2012)
Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study
Michael E. Weinblatt et al.
RHEUMATOLOGY (2012)
2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS CARE & RESEARCH (2012)
The Effects of Golimumab on Radiographic Progression in Rheumatoid Arthritis Results of Randomized Controlled Studies of Golimumab Before Methotrexate Therapy and Golimumab After Methotrexate Therapy
Paul Emery et al.
ARTHRITIS AND RHEUMATISM (2011)
Maintenance of Efficacy and Safety with Subcutaneous Golimumab Among Patients with Active Rheumatoid Arthritis Who Previously Received Intravenous Golimumab
Peter C. Taylor et al.
JOURNAL OF RHEUMATOLOGY (2011)
Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008
Kimme L. Hyrich et al.
RHEUMATOLOGY (2011)
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly
James B. Galloway et al.
RHEUMATOLOGY (2011)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Treating rheumatoid arthritis to target: recommendations of an international task force
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Golimumab, a New Human Anti-Tumor Necrosis Factor α Antibody, Administered Intravenously in Patients With Active Rheumatoid Arthritis Forty-Eight-Week Efficacy and Safety Results of a Phase III Randomized, Double-Blind, Placebo-Controlled Study
Joel Kremer et al.
ARTHRITIS AND RHEUMATISM (2010)
Subcutaneous Bioavailability of Golimumab at 3 Different Injection Sites in Healthy Subjects
Zhenhua Xu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Golimumab for Rheumatoid Arthritis: A Systematic Review
Jasvinder A. Singh et al.
JOURNAL OF RHEUMATOLOGY (2010)
Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
E. C. Keystone et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Golimumab, a Human Anti-Tumor Necrosis Factor α Monoclonal Antibody, Injected Subcutaneously Every Four Weeks in Methotrexate-Naive Patients With Active Rheumatoid Arthritis Twenty-Four-Week Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Golimumab Before Methotrexate as First-Line Therapy for Early-Onset Rheumatoid Arthritis
Paul Emery et al.
ARTHRITIS AND RHEUMATISM (2009)
Golimumab inpatients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
Josef S. Smolen et al.
LANCET (2009)
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice:: the Research in Active Rheumatoid Arthritis (ReAct) trial
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Pharmacokinetics and safety of golimumab, a fully human anti-TNF-α monoclonal antibody, in subjects with rheumatoid arthritis
Honghui Zhou et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
B. Combe et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Remission and active disease in rheumatoid arthritis - Defining criteria for disease activity states
D Aletaha et al.
ARTHRITIS AND RHEUMATISM (2005)
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial
C Grigor et al.
LANCET (2004)
Share Paper
